Myomo reports Q4 EPS (1c), consensus (2c)

Reports Q4 revenue $12.1M, consensus $9.9M. “Our success in the fourth quarter is the culmination of a transformational year for Myomo (MYO), as quarterly revenue surpassed $12 million, with double the unit volume compared to the prior year period and generating positive quarterly cash flows. I’m proud of our team achieving, and in many cases exceeding, the ambitious objectives we set for ourselves at the beginning of the year. We rapidly scaled our operations to serve the Medicare Part B population that is medically eligible to receive a MyoPro. We exited the year in the best position we’ve been in, and our objective is to repeat our success from this year in 2025,” said Paul R. Gudonis, CEO.